Selected epidemiological aspects of fresh whole blood application in the Polish Field Hospital in Afghanistan by Olszewski, Adam et al.
www.intmarhealth.pl 23
Int Marit Health 
2014; 65, 1: 23–27 
DOI: 10.5603/IMH.2014.0006 
www.intmarhealth.pl 
Copyright © 2014 Via Medica 
ISSN 1641–9251
REVIEW PAPER
Krzysztof Korzeniewski, MD, PhD, Professor at Military Institute of Medicine, Department of Epidemiology and Tropical Medicine, ul. Grudzińskiego 1, 81–103 Gdynia, 
Poland, e-mail: kktropmed@wp.pl
Selected epidemiological aspects of fresh whole blood 
application in the Polish Field Hospital in Afghanistan
Adam Olszewski1, Krzysztof Korzeniewski2, Anna Lass3
1Head of Prophylaxis and Treatment Department, Inspectorate of Military Health Service, Warsaw, Poland 
2Head of Epidemiology and Tropical Medicine Department in Gdynia, Military Institute of Medicine, Warsaw, Poland 
3Tropical Parasitology Department in Gdynia, Medical University of Gdansk, Poland
ABSTRACT
Minimisation of blood transmitted diseases is a basic element of all blood transfusion strategies. Civilian 
health service standards used in peacetime may be difficult to implement in a battlefield. The risk of blood
-borne diseases depends on the applied donor qualification procedures and the epidemiological situation 
in the areas of military operations. The authors discuss various epidemiological aspects considered when 
selecting potential donors of fresh whole blood for a Walking Blood Bank at the Polish Field Hospital in 
Afghanistan.
(Int Marit Health 2014; 65, 1: 23–27)
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INTRODUCTION
Despite increasingly sophisticated donor qualification 
procedures both for screening and pathogens inactivation, 
fresh whole blood (FWB) transfusions may still transmit 
diseases.
Since we have to supply FWB or components during mili-
tary operations in Iraq and Afghanistan, we had to establish 
the safest possible procedures for battlefield transfusions. 
Throughout the Operation Iraqi Freedom (OIF), which was 
carried out from 2003 to 2008, the Polish Field Hospital 
received blood components from the U.S. Forces health 
services, because the logistic unit of the Polish Armed For-
ces was incapable of maintaining regular supplies of fresh 
blood. Whole blood and components, which were used in 
the Polish Field Hospital came from military blood collection 
centres in the U.S., in emergency situations FWB was im-
mediately delivered to a battlefield by air [1]. Within a given 
time period, the U.S. health services operating in Iraq and 
Afghanistan implemented more complex procedures for 
collection and use of FWB in patients suffering from massive 
haemorrhage and associated coagulopathy. Thirty-six out of 
281 (13%) patients received FWB during the first 10 months 
of OIF, i.e. from March to December 2003 [2]. In terms of 
safety, the procedures for transfusion therapy in the area 
of operations differed from those adopted by civilian health 
services. In the period April–December 2004, only one 
U.S. Combat Support Hospital required that blood donors 
were screened for HIV, HCV and HBV [3]. In 2006, the U.S. 
Forces developed and implemented uniform procedures for 
collection and application of FWB in field hospitals, which 
were later published in the Joint Theater Trauma System 
Clinical Practice Guideline [4]. In order to improve safety 
of the transfusion therapy, the procedures are modified 
each year. The risk of transmitting a blood-borne disease 
in operational conditions is much higher than in the civilian 
environment. However, the use of FWB in patients suffering 
from massive haemorrhage and associated coagulopathy 
has become a common procedure in the U.S. military field 
hospitals in the theatre of operations.
The Polish Field Hospital in Afghanistan, also known as 
a Medical Support Group (MSG), was establish in 2010 and 
is located on the premises of the Forward Operating Base 
Ghazni (FOB Ghazni). Medical personnel serving in MSG car-
ry out tasks allocated to a Role 2 medical treatment facility 
— they cooperate with Forward Surgical Team (FST, Role 2, 
U.S. Forces medical facility located in the same military 
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base). Needless to say, it is necessary that both, the Polish 
and American coalition partners, implement the same me-
dical procedures. Due to the nature of injuries, e.g. massive 
haemorrhage, it is important that medical facilities operating 
in Afghanistan have the capability to supply an adequate 
amount of blood and its components to a battlefield. The 
total amount of FWB stored in the Polish MSG and in the 
American FST is insufficient. In 2012, Polish Field Hospital 
in Afghanistan adopted recommended procedures for FWB 
therapy in order to increase safety of patients. Additionally, 
Polish Military Contingent procured all necessary equipment 
and trained their medical personnel. Moreover, in order to 
ensure blood recipient safety, it was necessary to carry out 
medical investigation inside the area of operations, paying 
particular attention to the incidence of blood-transmitted 
infectious diseases.
SYSTEM OF FWB COLLECTION IN THE  
POLISH FIELD HOSPITAL IN AFGHANISTAN
The basic element of FWB collection system in the Polish 
Field Hospital in Afghanistan is selecting sufficient number 
of potential donors of fresh whole blood for a Walking Blood 
Bank (WBB). The rules regarding donor selection in a mis-
sion area are different from those applied by public blood 
donation centres in Poland. Polish blood donation centres 
act in accordance with the European Union directives as 
well as the national law, and thus they are obliged to meet 
a number of requirements regarding the use of FWB. One such 
requirement is that whole blood or its components can only 
be used if it had been screened for markers of blood-borne 
pathogens. In the operational conditions, and especially in 
mass casualty situations, screening of FWB is not always 
possible. In the peacetime, whole blood or components 
must undergo a series of tests for blood-transmitted patho-
gens before they are approved for therapeutic use. FWB 
must be tested for: HBs antigen, anti-HIV 1 and 2 antibod-
ies, anti-HCV antibodies, RNA HCV, DNA HBV, RNA HIV, and 
syphilis. Blood samples for screening are collected during 
donations. Currently, the Polish Field Hospital in Afghanistan 
does not possess the capability to use methods of molecular 
biology for screening tests in emergency situations. They 
use serological tests instead. Those tests reduce, but do 
not eliminate, the risk of infection. Additionally, in order to 
facilitate the process of whole blood collection in emergency 
situations, all other procedures for selecting donors need 
to be maximally simplified, the least time-consuming, yet, 
possibly the safest.
EPIDEMIOLOGICAL ASPECTS OF FWB  
APPLICATION IN FIELD CONDITIONS
American experience shows that the risk of complica-
tions resulting from FWB transfusions (both for donors and 
recipients) is only slightly higher in a battlefield than in the 
civilian environment. This was confirmed by the data collect-
ed during the military operations in Iraq and Afghanistan and 
the retrospective analysis of more than 6,000 transfused 
units of FWB. In the period from 2003 to 2008, 2,831 whole 
blood samples were tested. HCV markers were detected in 
3 samples and HTLV (human T-lymphocyte virus) in 2 samples. 
FWB transfusions may certainly transmit infections, yet, the 
benefits from the application of FWB therapy exceed the 
potential risk [3, 4].
According to the data from the National Institute of 
Public Health — National Institute of Hygiene in Poland, 
the prevalence of viral hepatitis B was estimated at 3.9 per 
100,000 persons in 2009 and 4.3 per 100,000 persons in 
2010. The prevalence of viral hepatitis C was 5.1 in 2009 
and 5.2 in 2010. The prevalence of newly diagnosed HIV 
infections was estimated at 2.5 per 100,000 persons in 
both years [5]. In terms of epidemiology, the prevalence of 
diseases in the population of first-time donors corresponds 
to the prevalence observed in general population. The rates 
of infections amongst multi-time donors are lower than 
those observed in general population because of routine 
testing for blood-transmitted pathogens. As an example, 
the prevalence of HBs antigen amongst Polish first-time 
donors has been estimated at 0.5%, and this rate has not 
changed since 2009. While HBs antigen is rarely detected 
in the population of multi-time donors, its prevalence ranges 
from 0.001% to 0.0004%. As regards the prevalence of viral 
hepatitis C, the percentage of confirmed cases amounted 
to 0.36% in 2008 and 0.31% in 2011; in multi-time donors 
it was 0.01% and 0.02%, respectively. By contrast, HIV pre-
valence has increased from 0.98 per 100,000 donations in 
the period 2005–2007 to 2.04 in the period 2008–2010. 
It is alarming that the rise in HIV prevalence was also 
reported amongst multi-time donors [6]. According to the 
data published in the U.S. in 2008, the American Red 
Cross Blood Services collected 6,638,877 units of whole 
blood and blood components from 3,830,094 honorary 
blood donors, of whom 74% were multi-time donors. The 
prevalence of confirmed cases of infections per 100,000 
donors was as follows: HIV — 5.11% in first-time donors 
and 2.16% in multi-time donors; HCV — 10.38% in first-
time donors and 2.98% in multi-time donors; HBV — 6.34% 
in first-time donors and 2.62% in multi-time donors. The 
figures clearly demonstrate lower prevalence of infections 
amongst multi-time donors. The authors of the publication 
highlighted the fact that the number of HIV infections has 
remained at a stable level in multi-time donors, whereas 
it has fallen in the population of first-time donors [7]. The 
introduction of molecular biology methods to screen blood 
donor lowers the risk of transmitting infections, because 
it reduces the window period and makes it possible to 
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detect genetic material of viruses before the appearance 
of antibodies. An estimated risk of transmitting HBV, HCV 
and HIV infections for different blood donor screening 
methods is presented in Tables 1 and 2.
In terms of epidemiology, it is important to pay attention 
to parasitic diseases, as well as some viral infections caused 
by hepatotropic viruses. The risk for developing a parasitic 
infection, such as leishmaniasis or malaria, is relatively low 
in the areas where Polish soldiers are stationed.
Polish military bases are located in the areas lying more 
than 2000 m above sea level, where vectors of infection 
(mosquitoes transmitting malaria or sand flies transmitting 
leishmaniasis) are absent. Cases of malaria diagnosed in 
Ghazni province are typically imported from the lowland re-
gions of the country. The incidence of malaria in Afghanistan 
has decreased over the last decade. In 2002, the World 
Health Organisation (WHO) estimated the number of malaria 
cases at 2.5–3 million per year. In 2008, the Afghan health 
service reported of 52,228 infections treated as malaria 
(21,148 cases were laboratory confirmed). The highest in-
cidence of malaria was reported in Nangarhar, Badakhsan 
and Kandahar provinces. The Ministry of Public Health in 
Afghanistan has divided the country into 3 epidemiological 
strata. There are 14 provinces in the high risk, 15 provinces 
in the low risk, and 5 provinces in the very low risk for trans-
mission. The majority of Polish military personnel have been 
deployed to Ghazni province, which is the stratum with the 
lowest risk of malaria transmission (Fig. 1).
Although the risk of malaria transmission in Ghazni 
province is relatively low, soldiers may become infected 
when they are relocated to different parts of the country. 
In 2010, a Polish soldier contracted malaria while he 
was carrying out his tasks in the vicinity of Jalalabad 
(Nangarhar province), where the risk for malaria transmis-
sion is high. Epidemiological interviews revealed that the 
majority of Polish soldiers serving in Afghanistan decide 
not to take anti-malarial chemoprophylaxis [10]. The 
questionnaires completed by Polish military personnel in 
the period 2012–2013 (DD572 Form) demonstrated that 
none of the soldiers selected for the WBB programme was 
using anti-malarial chemoprophylaxis throughout their 
stay in FOB Ghazni. Although the risk of transmitting ma-
laria via blood transfusion is low, it is necessary to screen 
blood donors for Plasmodium. Malaria detection tests, 
which were carried out in the period 2012–2013, all 
proved negative. Another parasitic disease, which may be 
transmitted through blood transfusion is leishmaniasis. 
The disease occurs in 3 clinical forms: cutaneous (CL), vis-
ceral (VL) and muco-cutaneous (MCL). Approximately 90% 
of all cases of cutaneous leishmaniasis are diagnosed in 
Afghanistan, Brazil, Peru, Iran, Saudi Arabia and Syria. 
Kabul, the capital city of Afghanistan, remains the largest 
reservoir of CL in the world, with 65,000 diagnosed cases 
[11]. As in the case of malaria, the risk for contracting 
leishmaniasis in the mountainous Ghazni province is 
relatively low. Owing to the fact that infection vectors 
(sand fly Phlebotomus) are present in areas lying below 
2000 m above sea level, military personnel deployed to 
Afghanistan is at risk of leishmaniasis during transfer to 
and from FOB Ghazni via Bagram Airfield, military base 
located 60 km from Kabul. Researchers have confirmed 
that leishmaniasis can be transmitted through blood 
transfusion. Intercellular form of Leishmania tropica and 
Leishmania donovani protozoa are able to survive up to 
30 days in FWB monocytes and in platelet concentrates 
if stored at the temperature of 4oC, and at least 5 days, 
if stored at the temperature of 24oC. Transfusion-trans-
mitted leishmaniasis was reported in China in 1948. At 
least 11 cases of post-transfusion infections with Leish-
mania parasites have been described in English-written 
medical literature so far. In 1991, Belgian researchers 
reported a case of transfusion-transmitted leishmaniasis 
Table 1. Estimated risk of transmitting infections for different blood donor screening methods (according to Stramer et al. [8])*
Virus Serological tests Molecular tests
In mini-pools In single donations
HIV 0.75 (1:1,300,000) 0.52 (1:1,900,000) 0.33 (1:3,000,000)
HCV 4.3 (1:230,000) 0.61 (1:600,000) 0.43 (1:2,300,000)
HBV 5.5 (1:180,000) 4.8 (1:210,000) 2.4 (1:410,000)
*Data refer to the United States, where the prevalence of HBV and HCV infection markers is lower than in Poland 
Source: Grabarczyk P et al. Practical consequences of HBV DNA screening implementation in blood donors. Acta Haematol Pol 2009; 40: 45–54 [9]
Table 2. Estimated risk of transmitting viral infections by trans-
fusion in the United States in 2012
Virus Whole blood or red blood cell products
HBV 1:280,000–1:355,000
HCV 1:1,000,000–1:2,000,000
HIV 1:1,500,000–1:2,000,000
Source: UpToDate. Risk of viral infection following transfusion of blood products. 
Available at: www.uptodate.com. Accessed: Feb 2014
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in an 11-month infant, who had never travelled abroad 
[12]. With regard to transfusion safety, medical personnel 
need to be aware that asymptomatic parasitemia may 
persist for several weeks or even months, as is the case 
of Leishmania donovani.
Currently, there is no comprehensive epidemiological 
data available on blood-borne viral diseases occurring in 
the Afghan population. Studies conducted in the period 
2003–2011 demonstrated HBV infections in 1.9% and 
HCV infections in 1.1% of the studied population (132 
thousands of individuals). It is a well-known fact that hepa-
totropic viruses are mainly transmitted through the use 
of contaminated needles, unprotected sex or the use of 
untested blood. Research carried out in the Central Blood 
Bank in Kabul from March to December 2006 demonstrat-
ed that the prevalence of HBsAg in blood donors was 3.9%, 
and the prevalence of anti-HCV antibodies — 1.9% [13]. 
According to the reports published by the Ministry of Public 
Health of the Islamic Republic of Afghanistan (MoPH IRA), 
approximately 5,000 of Afghan citizens are infected with 
HIV. Nevertheless, there is no accurate data available on 
the prevalence of HIV in the blood donor population. The 
WHO estimated the HIV incidence rate at 100 cases per 
100,000 donations. Due to the fact that military personnel 
operating in Afghanistan have limited contact with the local 
population and a self-sufficient system of medical support, 
the local epidemiological situation with respect to HBV, 
HCV and HIV transmission rates is of little importance to 
military contingents.
THE EXECUTION OF WALKING BLOOD 
BANK PROGRAMME IN AFGHANISTAN
The majority of Polish soldiers selected for Walking 
Blood Bank are active blood donors. Before being select-
ed for WBB, a candidate has to complete a shortened 
questionnaire, which is uniform with the one used by 
the U.S. Forces health services. Candidates, who do not 
fulfill the mandatory requirements are disqualified from 
the programme. Once they have been selected, potential 
blood donors need to undergo a series of laboratory ex-
amination, including a complete blood count and tests for 
HIV, hepatitis B and C, syphilis and malaria. In emergency 
situations, all blood tests are performed retrospectively. 
Additionally, tests for AB0 group antigens and Rh group D 
antigen are carried out. The results of all tests performed 
in Afghanistan are retrospectively verified in Poland, se-
rum samples (obtained by centrifugation) are transported 
to Polish laboratories and tested by means of molecular 
biology techniques. In order to detect viral infections in 
blood donors, rapid immunochromatographic tests are 
used. The sensitivity and specificity of the tests comply 
with the recommendations formulated by the WHO (99.5%) 
[14]. Immunochromatographic tests are also used for 
detecting malaria. In the case of Plasmodium falciparum, 
their sensitivity is 99.4%, and in the case of Plasmodium 
vivax it is 95%, their specificity is 99.3% for both species 
of Plasmodium. It is worth mentioning that such tests are 
not ordinarily performed in Poland, because Central Europe 
is a non-endemic area for malaria.
Figure 1. Stratification map of malaria in Afghanistan; Source: Islamic Republic of Afghanistan, Ministry of Public Health, Kabul 2008
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All tests, which are carried out in the Polish Military Con-
tingent in Afghanistan are retrospectively verified in the Mili-
tary Blood Donation and Blood Therapy Centre in Poland 
(all the tests performed so far proved negative). The transcrip-
tion mediated amplification method is used for this purpose. 
The data on the Walking Blood Bank programme in the Polish 
Field Hospital in Afghanistan are presented in Table 3.
In emergency situations, when there is no time to per-
form any prospective diagnostics (not even immunochro-
matographic tests), blood donors are selected on the basis 
of epidemiological interview and medical examination. 
A potential blood donor needs to complete the U.S. Army 
DD 572 Form, which was earlier modified and adapted for 
the purposes of the Polish Military Contingent. Candidates 
selected for the WBB programme are not screened for 
leishmaniasis, as there is no legal requirement to perform 
such a test. Screening blood donors for leishmaniasis 
has been discussed, but because the transmission risk 
is low, the introduction of routine testing is pointless. 
Taking into consideration the epidemiological situation 
regarding leishmaniasis, it is important that candidates 
for FWB donors undergo a careful medical examination. 
Both ulcerative skin lesions (CL) or lymphadenopathy (VL) 
disqualify candidates from the WBB programme.
CONCLUSIONS
In order to provide adequate medical support to per-
sonnel operating in harsh conditions, we ought to introduce 
such medical procedures, which take into consideration 
local epidemiological situation and the type of tasks per-
formed in the field conditions. Maintaining regular supplies 
of FWB and its components to a battlefield is one of the 
most difficult tasks that military health services are to 
handle. Civilian health service standards regarding FWB 
collection are impossible to implement in combat condi-
tions. However, the experience of medical services sup-
porting the Polish Military Contingent in Afghanistan in the 
period 2011–2013 shows that the use of FWB in military 
environment is sometimes necessary, regardless of the 
risk. As it has already been mentioned, the epidemiological 
situation regarding blood-borne diseases in Afghanistan is 
stable. Therefore, the collection and use of FWB appears 
to be relatively safe. In order to ensure safety of therapy, 
both prospective and retrospective diagnostic tests are 
performed. They include immunochromatographic and 
molecular biology techniques. Moreover, epidemiological 
interviews and physical examination of potential blood 
donors also increase safety of fresh whole blood therapy.
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